FXIII-A Leu34 genetic variant in premature coronary artery disease: A genotype – phenotype case control study

Johanne Silvain; Ana Pena; Jean-Baptiste Vignalou; Jean-Sébastien Hulot; Sophie Galier; Guillaume Cayla; Anne Bellemain-Appaix; Olivier Barthélémy; Farzin Beygui; Claire Bal-dit-Sollier; Ludovic Drouet; John W. Weisel; Gilles Montalescot; Jean-Phillippe Collet

doi:10.1160/TH11-01-0027

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 106(03): 511-520
DOI: 10.1160/TH11-01-0027

Cardiovascular Biology and Cell Signalling

Schattauer GmbH

FXIII-A Leu34 genetic variant in premature coronary artery disease: A genotype – phenotype case control study

Johanne Silvain

¹Institut de Cardiologie, INSERM UMRS 937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France

,

Ana Pena

¹Institut de Cardiologie, INSERM UMRS 937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France

,

Jean-Baptiste Vignalou

¹Institut de Cardiologie, INSERM UMRS 937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France

,

Jean-Sébastien Hulot

²Pharmacogenomic unit, INSERM UMRS 621, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France

,

Sophie Galier

¹Institut de Cardiologie, INSERM UMRS 937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France

,

Guillaume Cayla

¹Institut de Cardiologie, INSERM UMRS 937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France

,

Anne Bellemain-Appaix

¹Institut de Cardiologie, INSERM UMRS 937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France

,

Olivier Barthélémy

¹Institut de Cardiologie, INSERM UMRS 937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France

,

Farzin Beygui

¹Institut de Cardiologie, INSERM UMRS 937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France

,

Claire Bal-dit-Sollier

³Institut des Vaisseaux et du Sang, CHU – Lariboisière – Paris, France

,

Ludovic Drouet

³Institut des Vaisseaux et du Sang, CHU – Lariboisière – Paris, France

,

John W. Weisel

⁴Department of Cell and Developmental Biology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

,

Gilles Montalescot

¹Institut de Cardiologie, INSERM UMRS 937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France

,

Jean-Phillippe Collet

¹Institut de Cardiologie, INSERM UMRS 937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France

› Author Affiliations

Abstract

Summary

The FXIII-A Leu34 genetic variant increases and accelerates fibrin stabilisation; however, its association with premature coronary artery disease (CAD) and thrombotic events remains controversial. FXIII Val34Leu genotype was determined in 242 young individuals (<45 years old) who survived a myocardial infarction (MI) and 242 healthy controls matched for age and gender. We evaluated its effect on longterm clinical outcome defined as a composite of cardiovascular death, recurrent MI and urgent revascularisation. In addition, fibrin clot stiffness (elastic modulus or EM) and response to rt-PA-mediated fibrinolysis (fibrinolysis rate) were measured ex vivo using the Hemodyne analyser and confocal microscopy as surrogate endpoint. FXIII-A Leu34 genetic variant was not associated with premature CAD (adj. odds ratio 0.83 [0.49–1.4]) nor did it influence clinical outcome in patients, during a median follow-up of 6.3 (± 2.4) years. Patients produced stiffer fibrin clots (median [IQR] EM =20.3 [14.9–28.1] vs. 12.8 [9.6–17.1] kdynes/ cm²; p<0.0001) and displayed reduced response to fibrinolysis with lower fibrinolysis rate (6.7 [3.4–11.0] vs. 9.0 [5.0–16.7] sec-¹x10⁻⁴; p<0.0001) than healthy controls. Carriage of factor XIII-A Leu34 led to a stepwise decrease in fibrinolysis rate with a significant gene–dose-effect in patients (7.7 [4.1–12.2] vs. 4.8 [3.0–8.5] vs. 4.3 [2.4–8.1] sec-¹x10⁻⁴, for wild-type, heterozygous and homozygous, p for trend =0.003) and a non-significant trend in controls (p=0.01). In conclusion, FXIII-A Leu34 is a polymorphism which provides a strong resistance to fibrinolysis with a gene-dose effect, but does not relate to premature CAD or to recurrent coronary events in this study.

Keywords

Factor XIII Val34Leu - pharmacogenetic - fibrinolysis - thrombosis - coronary disease - fibrin structure

Full Text

References

References
1 Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-963.
2 Ryan EA, Mockros LF, Weisel JW. et al. Structural origins of fibrin clot rheology. Biophys J 1999; 77: 2813-2826.
3 Collet JP, Allali Y, Lesty C. et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
4 Collet JP, Soria J, Mirshahi M. et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82: 2462-2469.
5 Collet JP, Montalescot G, Soria J. et al. Pharmacological remodeling of the thrombus architecture. Blood Coagul Fibrinolysis 1999; 10 (Suppl. 01) S49-53.
6 Fatah K, Silveira A, Tornvall P. et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540.
7 Mills JD, Ariens RA, Mansfield MW. et al. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-1942.
8 Hancer VS, Diz-Kucukkaya R, Bilge AK. et al. The association between factor XIII Val34Leu polymorphism and early myocardial infarction. Circ J 2006; 70: 239-242.
9 Marin F, Gonzalez-Conejero R, Lee KW. et al. A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. J Am Coll Cardiol 2005; 45: 25-29.
10 Marin F, Corral J, Roldan V. et al. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. J Mol Cell Cardiol 2004; 37: 699-704.
11 Franco RF, Pazin-Filho A, Tavella MH. et al. Factor XIII val34leu and the risk of myocardial infarction. Haematologica 2000; 85: 67-71.
12 Marin F, Roldan V, Sogor F. Factor XIII Val34Leu polymorphism and premature myocardial infarction. Rev Esp Cardiol 2002; 55: 1106-1107.
13 Lim BC, Ariens RA, Carter AM. et al. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-1431.
14 Collet JP, Hulot JS, Pena A. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-317.
15 Silvain J, Collet JP, Nagaswami C. et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011; 57: 1359-1367.
16 Collet JP, Park D, Lesty C. et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-1361.
17 Weisel JW. The mechanical properties of fibrin for basic scientists and clinicians. Biophys Chem 2004; 112: 267-276.
18 Undas A, Zawilska K, Ciesla-Dul M. et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-4278.
19 Scott EM, Ariens RAS, Grant PJ. Genetic and Environmental Determinants of Fibrin Structure and Function Relevance to Clinical Disease. Atheroscler Thromb Vasc Biol 2004; 24: 1558-1566.
20 Ariens RA, Lai TS, Weisel JW. et al. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 2002; 100: 743-754.
21 de Lange M, Andrew T, Snieder H. et al. Joint linkage and association of six single-nucleotide polymorphisms in the factor XIII-A subunit gene point to V34L as the main functional locus. Arterioscler Thromb Vasc Biol 2006; 26: 1914-1919.
22 Schroder V, Kohler HP. Effect of factor XIII Val34Leu on alpha2-antiplasmin incorporation into fibrin. Thromb Haemost 2000; 84: 1128-1130.
23 Endler G, Funk M, Haering D. et al. Is the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease?. Br J Haematol 2003; 120: 310-314.
24 Roldan V, Corral J, Marin F. et al. Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. Am J Cardiol 2003; 91: 1242-1245.
25 Rallidis LS, Politou M, Komporozos C. et al. Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost 2008; 99: 1085-1089.
26 Bronic A, Ferencak G, Zadro R. et al. Impact of FXIII-A Val34Leu polymorphism on coronary artery disease in Croatian patients. Mol Biol Rep 2009; 36: 1-5.
27 Shafey M, Anderson JL, Scarvelis D. et al. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 2007; 97: 635-641.
28 Voko Z, Bereczky Z, Katona E. et al. Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis. Thromb Haemost 2007; 97: 458-463.
29 Carter AM, Cymbalista CM, Spector TD. et al. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007; 27: 2783-2789.
30 Bereczky Z, Balogh E, Katona E. et al. Modulation of the risk of coronary sclerosis/ myocardial infarction by the interaction between factor XIII subunit A Val34Leu polymorphism and fibrinogen concentration in the high risk Hungarian population. Thromb Res 2007; 120: 567-573.
31 Jorneskog G, Egberg N, Fagrell B. et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 1996; 39: 1519-1523.
32 Mannila MN, Eriksson P, Ericsson CG. et al. Epistatic and pleiotropic effects of polymorphisms in the fibrinogen and coagulation factor XIII genes on plasma fibrinogen concentration, fibrin gel structure and risk of myocardial infarction. Thromb Haemost 2006; 95: 420-427.
33 Dunn EJ, Ariens RA, De Lange M. et al. Genetics of fibrin clot structure: a twin study. Blood 2004; 103: 1735-1740.
34 Bereczky Z, Katona E, Muszbek L. Fibrin stabilization (factor XIII), fibrin structure and thrombosis. Pathophysiol Haemost Thromb 2004; 33: 430-437.
35 Collet JPh, Nagaswami S, Farell D. et al. Influence of gA/g’A fibrinogen on fibrin physical properties and fibrinolysis speed. Arterioscler Thromb Vasc Biol 2004; 24: 382-386.
36 Mannila MN, Lovely RS, Kazmierczak SC. et al. Elevated plasma fibrinogen gamma’ concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost 2007; 5: 766-773.
37 Lovely RS, Kazmierczak SC, Massaro JM. et al. Gamma’ fibrinogen: evaluation of a new assay for study of associations with cardiovascular disease. Clin Chem 2010; 56: 781-788.
38 Ajjan RA, Standeven KF, Khanbhai M. et al. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol 2009; 29: 712-717.
39 Undas A, Celinska-Lowenhoff M, Lowenhoff T. et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4: 1029-1036.
40 de la Red G, Tassies D, Espinosa G. et al. Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. Thromb Haemost 2009; 101: 312-316.
41 Hernandez-Romero D, Marin F, Lee KW. et al. Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction. Thromb Haemost 2010; 104: 650-652.
42 Uitte de Willige S, Standeven KF, Philippou H. et al. The pleiotropic role of the fibrinogen gamma’ chain in hemostasis. Blood 2009; 114: 3994-4001.